BPC-157 vs KPV
BPC-157 and KPV are short unapproved peptides that have both been studied in animal models of intestinal inflammation 3,8. BPC-157 is a 15-amino-acid peptide reported to derive from a gastric juice protein, while KPV is a three-residue fragment of alpha-melanocyte-stimulating hormone 2,8. BPC-157 has a few small human reports and an FDA advisory committee review, whereas no published human study of KPV was identified 3,8,9.
Side by side
| Field | BPC-157 | KPV |
|---|---|---|
| Class | Synthetic pentadecapeptide 2 | Melanocortin-derived tripeptide 8 |
| Origin and structure | 15 residues (GEPPPGKPADDAGLV), described as a stable gastric pentadecapeptide 2 | Lys-Pro-Val, alpha-MSH residues 11-13 8 |
| Proposed mechanism | Not established; FDA states that molecular targets have not been identified 3 | In human intestinal and T-cell lines, nanomolar KPV inhibited NF-kappaB and MAP kinase signaling after uptake via the PepT1 transporter 9 |
| Half-life | FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use 3 | Not identified in the sources reviewed |
| Highest human trial phase | Small uncontrolled pilot reports and an abstract-only randomized study described by FDA 3,4,5,6 | No human trial identified |
| FDA status | Not approved; listed among compounding substances that may present significant safety risks (nomination withdrawn); reviewed by FDA's advisory committee in July 2026 3,11 | Not approved; no Drugs@FDA record returned; listed among compounding substances for which FDA identified no human exposure data (nomination withdrawn) 11,13 |
| Published human outcomes | In a 17-person retrospective knee-pain chart review, 11 of 12 who received BPC-157 alone self-reported improvement, without validated function measures 4 | None identified |
| Safety signals | FDA judged clinical safety information insufficient and cited immunogenicity and impurity concerns 3,11 | FDA states it has not identified human exposure data and lacks information on whether KPV would cause harm 11 |
| WADA status | Named in S0 (non-approved substances); prohibited at all times 12 | Not named in the 2026 List; S0 covers substances without current governmental approval for human use 12 |
| Evidence level | Mostly rodent and cell studies, largely from one research group; very small human reports 1,3,7 | Mouse colitis models and cell lines only 8,9,10 |
BPC-157: what the data says
BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) described as a stable gastric pentadecapeptide 2. Reviews from the Zagreb group that has published much of the literature report effects in rat models of skin, gastrointestinal and other wounds 1. In a rat Achilles tendon transection model, BPC 157 was associated with better biomechanical, functional and microscopic recovery than saline (animal data) 2. FDA's 2026 briefing for its advisory committee stated that molecular targets have not been identified and found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal use 3.
Human reports are small and uncontrolled: a retrospective chart review of 17 people with knee pain, a 12-woman interstitial cystitis pilot, and an intravenous infusion study in 2 adults that reported no side effects 4,5,6. A 2025 systematic review of orthopaedic sports-medicine uses included 36 studies, of which 35 were preclinical and 1 was clinical 7.
KPV: what the data says
KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11-13 of alpha-MSH 8. In mouse DSS colitis and CD45RB-high transfer colitis, KPV was associated with earlier body-weight recovery and reduced histological inflammation, and it also reduced inflammation in mice with a nonfunctional melanocortin-1 receptor (animal data) 8.
In human intestinal epithelial and T-cell lines, nanomolar KPV inhibited NF-kappaB and MAP kinase signaling and reduced pro-inflammatory cytokine secretion, an effect linked to uptake through the PepT1 transporter (cell data) 9. Hyaluronic acid-functionalized nanoparticles carrying KPV reduced mucosal damage and TNF-alpha in a mouse colitis model 10. No human clinical study of KPV was identified in the sources reviewed 8,9,10.
Key research differences
- Size and origin: BPC-157 has 15 residues and is described as a gastric peptide, while KPV has 3 residues and is a fragment of alpha-MSH 2,8.
- Mechanism: a cell-level mechanism (PepT1 uptake and NF-kappaB inhibition) has been proposed for KPV, whereas FDA states that BPC-157's molecular targets are not identified 3,9.
- Human data: BPC-157 has a few small uncontrolled human reports, while no human study of KPV was identified 4,5,6.
- Regulatory review: BPC-157 went before FDA's Pharmacy Compounding Advisory Committee in July 2026; for KPV, FDA states it has no human exposure data 3,11.
- Sport: BPC-157 is named in WADA's S0 class, while KPV is not named on the 2026 List 12.
Where the evidence is limited
No study comparing BPC-157 and KPV was identified. KPV evidence is limited to mouse colitis models and cell lines 8,9,10. BPC-157 evidence is mainly from rodents, much of it from a single research group, and its human reports are small, uncontrolled and short 1,3,4,5,6. FDA found the clinical safety information for BPC-157 insufficient to characterize a safety profile and has no human exposure data for KPV 3,11.
Frequently asked questions
Are BPC-157 and KPV related?
Have either been studied for gut inflammation?
Is there human data on KPV?
What has FDA said about BPC-157?
References
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Frontiers in Pharmacology. 2021
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research. 2003
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 FDA. 2026
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine. 2021
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine. 2024
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine. 2025
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal. 2025
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Inflammatory Bowel Diseases. 2008
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology. 2008
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Molecular Therapy. 2017
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA (Human Drug Compounding). 2026
- International Standard: Prohibited List 2026 WADA. 2026
- Drugs@FDA application data queried through openFDA for KPV (no matching application record returned) (queried 22 October 2026) openFDA / Drugs@FDA. 2026
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.